Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial

Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor-T cell (CAR-T) immunotherapy approved for patients (pts) with relapsed/refractory multiple myeloma (RRMM). In the phase 3 trial CARTITUDE-4 (NCT04181827), cilta-cel demonstrated improved efficacy vs standard of care (SOC; daratumumab plus pomalidomide and dexamethasone [DPd] or pomalidomide plus bortezomib and dexamethasone [PVd]) with an overall response rate (ORR) of 84.6% vs 67.3% and ≥complete response (CR) of 73.1% vs 21.8%.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Doris K Hansen, Xiaoxiao Lu, Omar Castaneda, Sonja Sorensen, Saad Z. Usmani, Eileen Zhang, Stephen Huo, Sundar Jagannath Tags: 519 Source Type: research